The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Incidence of Hepatitis A in Israel Following Universal Immunization of Toddlers
Abstract
CONTEXT: In Israel, the mean annual incidence of hepatitis A disease was 50.4 per 100 000 during 1993-1998. A 2-dose universal hepatitis A immunization program aimed at children aged 18 and 24 months (without a catch-up campaign) was started in 1999. OBJECTIVE: To observe the impact of toddlers-only universal vaccination on hepatitis A virus disease in Israel. DESIGN AND SETTING: Ongoing passive national surveillance of hepatitis A cases in Israel has been conducted since 1993 by the Ministry of Health. An active surveillance program in the Jerusalem district in 1999-2003 provided validation for the passive program. MAIN OUTCOME MEASURE: Incidence of reported hepatitis A disease, 1993-2004. RESULTS: Overall vaccine coverage in Israel in 2001-2002 was 90% for the first dose and 85% for the second dose. A decline in disease rates was observed before 1999 among the Jewish but not the non-Jewish population. After initiation of the program, a sharp decrease in disease rates was observed in both populations. The annual incidence of 2.2 to 2.5 per 100 000 during 2002-2004 represents a 95% or greater reduction for each year with respect to the mean incidence during 1993-1998 (P<.001). For children aged 1 through 4 years, a 98.2% reduction in disease was observed in 2002-2004, compared with the prevaccination period (P<.001). However, a sharp decline was also observed in all other age groups (84.3% [<1 year], 96.5% [5-9 years], 95.2% [10-14 years], 91.3% [15-44 years], 90.6% [45-64 years], and 77.3% [>or=65 years]). Among the Jewish population in the Jerusalem district, in whom the active surveillance program was successfully conducted, a more than 90% reduction of disease was demonstrated. Of the 433 cases reported nationwide in 2002-2004 in whom vaccination status could be ascertained, 424 (97.9%) received no vaccine and none received 2 doses. CONCLUSION: This universal toddlers-only immunization program in Israel demonstrated not only high effectiveness of hepatitis A vaccination but also marked herd protection, challenging the need for catch-up hepatitis A vaccination programs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical abstract of Israel
li-sṭaṭisṭiḳah, I. L. H.-M. (2001) · Central Bureau of Statistics eBooks · Cited by 1,235
(1999) · PsycEXTRA Dataset · doi:10.1037/e547812006-001 · Cited by 1,131
A Controlled Trial of a Formalin-Inactivated Hepatitis A Vaccine in Healthy Children
Werzberger, A., Mensch, B., Kuter, B., Brown, L., Lewis, J., Sitrin, R., Miller, W., Shouval, D., Wiens, B., Calandra, G., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199208133270702 · Cited by 540
Protection Against Hepatitis A by an Inactivated Vaccine
Innis, B. L. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510410040030 · Cited by 417
Hepatitis A in Day-Care Centers: A Community-Wide Assessment
Hadler, S. C., Webster, H. M., Erben, J. J., Swanson, J. E., & Maynard, J. E. (1980) · New England Journal of Medicine · doi:10.1056/nejm198005293022203 · Cited by 300
Clinical experience with an inactivated hepatitis A vaccine.
Clemens, R., Safary, A., Hepburn, A., Roche, C., Stanbury, W. J., & Andre, F. E. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.supplement_1.s44 · Cited by 223 · cited 1×
“Third, longterm protection is achieved by vaccination.(20,36-38) By adding a highly vaccinated cohort to our population each year, seropositivity should increase among the population, thus reducing not only disease but transmission potential.”
BackgroundArmstrong, G. L., & Bell, B. P. (2002) · Pediatrics · doi:10.1542/peds.109.5.839 · Cited by 203
Rosenblum, L. S., Villarino, M. E., Nainan, O. V., Melish, M. E., Hadler, S. C., Pinsky, P. P., Jarvis, W. R., Ott, C. E., & Margolis, H. S. (1991) · Journal of Infectious Diseases · doi:10.1093/infdis/164.3.476 · Cited by 182
Epidemiological patterns of hepatitis A in different parts of the world
Gust, I. D. (1992) · Vaccine · doi:10.1016/0264-410x(92)90544-t · Cited by 172
McMahon, B. J. (1996) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.1996.02170320079014 · Cited by 163
Inactivated hepatitis A vaccine: Reactogenicity, immunogenicity, and long‐term antibody persistence
van Damme, P., Thoelen, S., Cramm, M., de Groote, K., Safary, A., & Meheus, A. (1994) · Journal of Medical Virology · doi:10.1002/jmv.1890440425 · Cited by 158
THE EFFECT OF UNDERREPORTING ON THE APPARENT INCIDENCE AND EPIDEMIOLOGY OF ACUTE VHIAL HEPATITIS
Alter, M. J., Mares, A., Hadler, S. C., & Maynard, J. E. (1987) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114496 · Cited by 122
Vogt, R. L., LaRue, D. E., Klaucke, D. N., & Jillson, D. A. (1983) · American Journal of Public Health · doi:10.2105/ajph.73.7.795 · Cited by 116
Prevention of Hepatitis A with the Hepatitis A Vaccine
Craig, A. S., & Schaffner, W. (2004) · New England Journal of Medicine · doi:10.1056/nejmcp031540 · Cited by 115
Damme, P. V., Matheï, C., Thoelen, S., Meheus, A., Safary, A., & André, F. E. (1994) · Journal of Medical Virology · doi:10.1002/jmv.1890440422 · Cited by 103
Bialek, S. R., Thoroughman, D. A., Hu, D. C., Simard, E. P., Chattin, J., Cheek, J., & Bell, B. P. (2004) · American Journal of Public Health · doi:10.2105/ajph.94.6.996 · Cited by 102
The role of young children in a community-wide outbreak of hepatitis A
Smith, P. F., Grabau, J. C., Werzberger, A., Gunn, R. A., Rolka, H., Kondracki, S. F., Gallo, R. J., & Morse, D. L. (1997) · Epidemiology and Infection · doi:10.1017/s0950268897007462 · Cited by 100
André, F., Damme, P. V., Safary, A., & Banatvala, J. E. (2002) · Expert Review of Vaccines · doi:10.1586/14760584.1.1.9 · Cited by 84
Shouval, D., Ashur, Y., Adler, R., Lewis, J. A., Armstrong, M. E., Davide, J. P., McGuire, B., Kuter, B. J., Brown, L., Miller, W. J. W., et al. (1993) · Vaccine · doi:10.1016/0264-410x(93)90151-m · Cited by 76
Long‐term immunogenicity of an inactivated virosome hepatitis A vaccine
BOVIER, P. A., Bock, J., Loutan, L., Farinelli, T., Glueck, R., & Herzog, C. (2002) · Journal of Medical Virology · doi:10.1002/jmv.10244 · Cited by 75
Use of Hepatitis A Vaccine in a Community-Wide Outbreak of Hepatitis A
Craig, A. S., Sockwell, D., Schaffner, W., Moore, W. L., Skinner, J. T., Williams, I. T., Shaw, F. E., Shapiro, C. N., & Bell, B. P. (1998) · Clinical Infectious Diseases · doi:10.1086/514700 · Cited by 65
Regional variation in the cost effectiveness of childhood hepatitis A immunization
Jacobs, R. J., Greenberg, D. P., Koff, R. S., Saab, S., & Meyerhoff, A. S. (2003) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000091295.53969.6a · Cited by 61
Ginsberg, G. M., Slater, P. E., & Shouval, D. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00007-6 · Cited by 51
Rise in the Incidence of Viral Hepatitis in Israel Despite Improved Socioeconomic Conditions
Green, M. S., Block, C., & Slater, P. E. (1989) · Clinical Infectious Diseases · doi:10.1093/clinids/11.3.464 · Cited by 46
Zamir, C., Rishpon, S., Zamir, D., Leventhal, A., Rimon, N., & Ben‐Porath, E. (2001) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960100461 · Cited by 43
Cited by
(1999) · PsycEXTRA Dataset · doi:10.1037/e547812006-001 · Cited by 1,131
Bernal, W., Auzinger, G., Dhawan, A., & Wendon, J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60274-7 · Cited by 996
Lemon, S. M., Ott, J. J., Van Damme, P., & Shouval, D. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.08.034 · Cited by 336
Hepatitis A Virus: From Discovery to Vaccines
Martin, A., & Lemon, S. M. (2006) · Hepatology · doi:10.1002/hep.21052 · Cited by 299
Hepatitis A in the Era of Vaccination
Wasley, A. (2006) · Epidemiologic Reviews · doi:10.1093/epirev/mxj012 · Cited by 295
Metadata
- Authors
- Dagan, R.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-07-13
- Volume
- 294
- Issue
- 2
- Pages
- 202
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2106518612
- Cited by
- 261
- References
- 25
- FWCI
- 17.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.